1. A method of treating melanoma in a human, which comprises administering parenterally a therapeutically effective amount of one or more arsenic compounds to said human.

2. The method of claim 1, wherein said arsenic compound is arsenic trioxide.

3. The method of claim 2, wherein said arsenic trioxide is formulated as an ionic aqueous solution.

4. The method of claim 1, wherein the total daily amount administered is from about 10 μg to about 200 mg.

5. The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 150 mg.

6. The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 70 mg.

7. The method of claim 1, wherein the arsenic compound is administered intravenously.

8. The method of claim 1, wherein the arsenic compound is administered in combination with an effective amount of at least one other therapeutic.

9. The method of claim 8, wherein the other therapeutic agent is a chemotherapeutic or radiotherapeutic.

10. The method of claim 8, wherein the other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.

11. The method of claim 2, wherein the dose is varied according to the body weight of said human.